Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | ENPEP | Q07075 | 8/20 | 0.45 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CTSD | P07339 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29351403 | 0.94 | SLC7A5 (0.43) | ALDH1A1ENPEPSLC7A5CTSD | |
| SCHEMBL29351914 | 0.93 | ALDH1A1 (0.50) | ALDH1A1ENPEPSLC7A5L3MBTL1CTSD | |
| SCHEMBL9491298 | 0.93 | ALDH1A1 (0.53) | ALDH1A1ENPEPSLC7A5L3MBTL1CTSD | |
| SCHEMBL16698375 | 0.93 | ALDH1A1 (0.53) | ALDH1A1ENPEPSLC7A5L3MBTL1CTSD | |
| SCHEMBL9491302 | 0.93 | ALDH1A1 (0.53) | ALDH1A1ENPEPSLC7A5L3MBTL1CTSD | |
| SCHEMBL14941289 | 0.93 | ALDH1A1 (0.53) | ALDH1A1ENPEPSLC7A5L3MBTL1CTSD | |
| SCHEMBL30051564 | 0.90 | ALDH1A1 (0.47) | ALDH1A1ENPEPSLC7A5L3MBTL1CTSD | |
| SCHEMBL30904491 | 0.90 | CTSD (0.46) | ENPEPCTSD | |
| SCHEMBL29575915 | 0.90 | SLC7A5 (0.50) | ALDH1A1SLC7A5CTSDCA2CA1 | |
| SCHEMBL31720945 | 0.87 | PDCD1LG2 (0.48) | ALDH1A1ENPEPL3MBTL1CA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 8787 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230391872-A1 | B AND T LYMPHOCYTE ATTENUATOR (BTLA) MODULATORS AND METHOD OF USING SAME | ANAPTYSBIO, INC. | 2023-12-07 | — | — | US | claimed |
| EP-4271480-A1 | VEGF-REGULATING PEPTIDES | IDP Discovery Pharma, S.L. (ES) | 2023-11-08 | — | — | EP | claimed |
| CN-116685603-A | B and T lymphocyte attenuation factor (BTLA) modulators and methods of use thereof | 安奈普泰斯生物有限公司 | 2023-09-01 | — | — | CN | claimed |
| CN-116660543-A | Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof | 中国人民解放军陆军军医大学第一附属医院 | 2023-08-29 | — | — | CN | claimed |
| US-20230137562-A1 | TAU AGGREGATION INHIBITORS | ADRX, INC. | 2023-05-04 | — | — | US | claimed |
| US-20220363759-A1 | ANTIBODIES DIRECTED AGAINST T CELL IMMUNOGLOBULIN AND MUCIN PROTEIN 3 (TIM-3) | ANAPTYSBIO, INC. | 2022-11-17 | — | — | US | claimed |
| WO-2022144401-A1 | VEGF-REGULATING PEPTIDES | IDP DISCOVERY PHARMA, S.L. (ES) | 2022-07-07 | — | — | WO | claimed |
| CN-112409473-B | MrgD immune antigen fragment, MrgD antibody, preparation method and application thereof | 江苏省人民医院（南京医科大学第一附属医院） | 2022-05-03 | — | — | CN | claimed |
| CN-114729002-B | Eluent collection during antibody chromatography | MORPHOSYS AG (DE) | 2026-05-26 | — | — | CN | disclosed |
| CN-108290931-B | Novel polypeptides having affinity for PD-L1 | AFFIBODY AB (SE) | 2026-05-26 | — | — | CN | disclosed |
| CN-116209679-B | Antibody-drug conjugates containing anti-mesothelin antibodies and uses thereof | BIOTECHNOLOGY DEVELOPMENT CENTER (CN) | 2026-05-26 | — | — | CN | disclosed |
| CN-116348115-B | Combination of antibody-drug conjugate and PARP1 selective inhibitor | ASTRAZENECA UK LTD. (GB) | 2026-05-26 | — | — | CN | disclosed |
| CN-114080232-B | Extracellular vesicles for vaccine delivery | Lhasa Sales Co.,Ltd. (CH) | 2026-05-26 | — | — | CN | disclosed |
| CN-116410307-B | Neutralizing antibody for neutralizing SARS-CoV-2 in six strains and its application | TSINGHUA UNIVERSITY (CN) | 2026-05-26 | — | — | CN | disclosed |
| CN-107206072-B | Combination therapy of the T cell activating bispecific antigen binding molecule CD3 ABD folate receptor 1(FolR1) and a PD-1 axis binding antagonist | 豪夫迈·罗氏有限公司 | 2022-01-21 | — | — | CN | disclosed |
| CN-113952451-A | Combined medicine composition for treating cancer and application thereof | 北京东方百泰生物科技股份有限公司 | 2022-01-21 | — | — | CN | disclosed |
| CN-113960313-A | Exosome ALK fusion protein magnetic immunochemiluminescence detection kit | 上海思路迪医学检验所有限公司 | 2022-01-21 | — | — | CN | disclosed |
| CN-113966344-A | anti-BCMA antibody conjugates, compositions comprising the same, and methods of making and using the same | 细胞基因公司 | 2022-01-21 | — | — | CN | disclosed |
| CN-107614517-B | Antibodies against infectious diseases | 台北医学大学 | 2022-01-21 | — | — | CN | disclosed |
| CN-107847592-B | Antibodies against human CSF-1R for inducing lymphocytosis in lymphomas or leukemias | 豪夫迈·罗氏有限公司 | 2022-01-21 | — | — | CN | disclosed |